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We tested whether markers of systemic oxidant stress were detectable in 29 typical IPF
patients, and whether these increased after low level exercise. We obtained resting plasma
for measurement of amino terminal pro brain natriuretic peptide (NT-proBNP), and plasma
and urine samples for isoprostanes and total nitrite. Total antioxidant capacity (TAC) was
measured in plasma, and H2O2 was measured in urine. Subjects exercised ate50 W on a semi
recumbent bicycle until limited by dyspnea. Samples were obtained immediately after exer-
cise for measurement of the same variables.
Plasma and urine samples were also obtained at rest from 6 normal individuals over 40 years
of age solely to establish comparison values for NT-proBNP, nitrite, H2O2 and TAC assays.
Plasma NT-proBNP was high at rest and after exercise, suggesting pulmonary arterial hyper-
tension. IPF patients’ resting NT-proBNP concentrations apparently exceeded those of normal
controls. IPF plasma isoprostanes at rest exceeded the normals. IPF urine isoprostanes
increased significantly after exercise (P Z 0.047 by signed rank test); and, plasma TAC
decreased significantly after exercise (P < 0.001 by signed rank test). Neither plasma nor urine
nitrite changed significantly after exercise. H2O2 concentration was quite high after exercise in
some IPF subjects’ urine.
IPF patients demonstrate systemic oxidant stress at rest detectable as increased isopros-
tanes in the circulation. An increase in urine isoprostanes and a decrease in plasma TAC after
exercise suggest that reactive oxygen species (ROS) are produced during low level exercise
done by IPF patients.
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Idiopathic pulmonary fibrosis (IPF) is a progressive, fibrotic
lung disease of unknown etiology prevalent in males over 50
years of age.1,2 Patients with IPF have evidence of oxidant
stress within the bronchoalveolar compartment and
circulation.3,4
Several structurally unrelated antioxidants inhibit bleo-
mycin (BLM)-induced lung injury. N-acetylcysteine (N-Ac)
protects rats from bleomycin-induced fibrosis.5,6 Transgenic
mice that over express extracellular superoxide dismutase
(EC-SOD) are protected from BLM-induced lung fibrosis.7 A
catalytic metalloporphyrin with SOD and catalase activity
also attenuates bleomycin-induced pulmonary fibrosis.8
Suppression of the transcription factor Nrf-2, which regu-
lates many aspects of the antioxidant response, in mice
worsens BLM-induced pulmonary fibrosis.9 Perhaps most
important, N-Ac has been found to minimize significantly the
progression of pulmonary function worsening in IPF patients,
who were also treated with prednisone and azathioprine.10
N-Ac has been shown to prevent epithelial-mesenchymal
transition of alveolar epithelial cells while repleting cellular
glutathione and decreasing reactive oxygen species (ROS)
production stimulated by transforming growth factor-beta
(TGF-b).11
Fluid recovered from IPF lungs by bronchoalveolar
lavage (BAL) contains high concentrations of myeloperox-
idase (MPO), and alveolar inflammatory cells release
increased quantities of superoxide anion (O2
e) and its dis-
mutation product, H2O2.
12 Alveolar ELF GSH concentration
was decreased by 77% in IPF patients compared to normal
controls (where [GSH] Z 429  34 mM).13 Suppression of
oxidant stress is in part responsible for the apparent clinical
effectiveness of N-acetylcysteine.14
Oxidative stress may trigger production or activation of
growth factors and cytokines and regulate matrix metal-
loproteinases (MMP) that promote fibrosis.15 ROS, which
may come from activated inflammatory cells, increase
release of transforming growth factor-beta (TGF-b) from
epithelial cells and activate it. TGF-b activation decreases
cellular glutathione, and its activation is a pivotal event in
the pathogenesis of fibrosis.16
Exercise limitation of IPF patients is also related to
a combination of decreased oxygen delivery and increased
pulmonary vascular resistance. Hypoxia causes increased
O2
- production by mitochondrial complex III, so H2O2 would
be anticipated to diffuse from muscle cells if scavenging
mechanisms were overwhelmed. An underlying rationale
for the present study is therefore that oxidant stress may
be detected in the systemic circulation, when IPF patients
exercise at a low workload and develop hypoxemia.
We designed this pilot study to measure markers of
systemic oxidant stress in clinically typical IPF patients who
were to be enrolled in a randomized controlled trial of silde-
nafil (see http://clinicaltrials.gov/ct2/show/NCT00359736?
termZipfþANDþsildenafil&rankZ4). Previous studies have
not examined well defined IPF cohorts.4 Detailed demo-
graphicdataand resultsof that trial are reportedelsewhere.17
We hypothesized that classical markers of reactive oxygen
species (ROS) in the plasma and urine, including isoprostanes
and total antioxidant capacity (TAC) would demonstrateoxidant stress at rest and be increased in IPF subjects by low
level exercise. We measured amino terminal pro brain natri-
uretic peptide (NT-proBNP) and estimated systolic pulmonary
artery pressures (PAPsys) by echocardiography to determine if
the subjects were at risk of pulmonary hypertension.18 Our
results demonstrated that typical IPF patients, who often
have elevated NT-proBNP levels, develop hypoxemia andmild
lactic acidosis that is associated with increased urinary iso-
prostanes and decreased plasma total antioxidant capacity
during exercise at a low power output.
Methods
Experimental design
IPF was defined according to the American Thoracic and
European Respiratory Societies (ATS-ERS) clinical diagnostic
criteria.1 We studied 29 IPF patients who were to begin
a double blind, randomized, placebo controlled trial of sil-
denafil as a potential therapy for patients with moderate
impairment of pulmonary function and mild to moderate
increases in echocardiographically estimated systolic
pulmonary artery pressure (range 25e50 mm Hg). Patients
were studied in this protocol before they received the
experimental drug or placebo. Subjects did not undergo right
heart catheterization. Pulmonary function tests, including
arterial blood gases, were obtained before entry into the
trial. Patients were recruited between August 2006 and
November 2008. All subjects and normal controls provided
written informed consent.
We also obtained plasma and urine samples from six
volunteers, who were laboratory employees. Two of the six
were female. The average age was 50  6 (SD) years, and
the average weight was 76  16 (SD) kg. None of the
volunteers smoked, and none had any evident pulmonary
disease. Plasma and urine samples from the controls were
used only to standardize the assays and provide a range of
expected values. The controls did not participate in the
exercise protocol.
This study was reviewed and approved by the Miami
VAHS Institutional Review Board as protocol 4549.04.
Exercise test protocol to quantify dyspnea
Subjects underwent standardized 50-W exercise bicycle
challenges immediately before the 6-month drug inter-
vention. We chose this constant low level power output to
test endurance. The subjects had also completed 6-min
walk tests, which are reported elsewhere.17 Patients used
sufficient supplemental oxygen to maintain pre-exercise
oxygen saturation at 90% or greater, only if needed. Exer-
cise was done in the sitting position on a semi recumbent
bicycle (Life Fitness 95Ri, Life Fitness USA). It consisted of
pedaling at 50e60 revolutions/minute at a constant work-
load of 50 W. This approximates an energy expenditure of
three metabolic equivalents (MET; where 1 MET Z 3.5 mL
O2/kg/minute). Exercise continued until patients were
limited by dyspnea or fatigue. O2 saturation, pulse rate,
blood pressure and Borg dyspnea score were monitored and
recorded before and immediately after pedaling. Total
exercise time (seconds) was recorded.
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We collected blood and urine samples in the resting state
before and immediately after the standardized exercise.
Blood samples were collected by venipuncture in two 10 mL
tubes containing sodium heparin (BD Vacutainer 366480,
Franklin Lakes, NJ). Plasma was separated by centrifuga-
tion (1500  g for 10 min at 4 C) and multiple aliquots were
stored at 80 C until analysis. Urine samples were stored
in multiple aliquots at 80 C until analysis. Samples were
thawed only once before assays.
BNP assays
NT-proBNP was assayed using the automated assay
described in detail by Elin and Winter.19
Plasma lactate assays
The concentration of lactate in plasma samples obtained
before and after exercise was determined using an enzy-
matic assay as described.20 Blood sampleswere placed on ice
and plasma was separated as rapidly as possible. Samples
were stored frozen at 80 C until assays were done.
Urine creatinine assays
Urine creatinine was assayed by the clinical laboratory at
the Miami VAHS, using an automated assay.
Isoprostane measurements
We quantified F2-isoprostanes in plasma and urine using
high performance liquid chromatography (HPLC) tandem
mass spectroscopy (MSeMS) as described in detail.21
Plasma and urine samples were stored at 80 C until
analysis (although isoprostanes are resistant to degrada-
tion during handling). The HPLC system consisted of Agilent
Series 110 components (Agilent, Waldbronn, Germany).
The HPLC system was interfaced with a triple quadrupole
mass spectrometer (ADI 4000, Applied Biosystems, Foster
City, CA) run in the negative multiple reaction model. HPLC
systems and mass spectrometer were controlled by Analyst
software (Version 1.3.1, Applied Biosystems). 500 mL
samples were injected. The assay has been validated
according to FDA Center for Drug Evaluation and Research
Guidelines for bio analytical method validation.
Assays were done at the University of Colorado Health
Sciences Center. Normal values for 15-F2 -isoprostanes have
been established by this laboratory for plasma (range
3e25 ng/L; n Z 16) and urine (55e348 ng/mg creatinine;
n Z 16) using this technique and equipment. These values
were used for comparison with the pre- and post-exercise
isoprostane data obtained in our subjects.
Nitrate/nitrite assays
We measured total nitrite in plasma and urine as a mar-
ker of NO production at rest and after exercise using
a nitrate/nitrite colorimetric assay (Kit No. 780001,Cayman Chemical Company, Ann Arbor, Michigan). Nitrate
reductase was used to reduce all nitrate to nitrite before
measurement.22,23 Plasma samples were ultrafiltered
through a 10 kDa molecular weight cut-off filter (Amicon)
that had been rinsed by centrifugation with ultrapure
water. The detection limit of the assay is about 1 mM
nitrite. Urine typically contains 200e2000 mM nitrite, and
so urine samples were diluted before assay. Urine nitrite
concentration was expressed as nmoles/milligram
creatinine.
Total antioxidant capacity
We determined the Trolox equivalent total antioxidant
capacity (TAC) of plasma before and after each stan-
dardized exercise test. This assay quantifies the ability of
the sample to inhibit an in vitro oxidation assay, and
compares the degree of inhibition by plasma to known
quantities of Trolox (Antioxidant Assay Kit No. 709001,
Cayman Chemical Company, Ann Arbor, Michigan). It relies
on the ability of low molecular weight antioxidants in
plasma to inhibit oxidation of 2, 20-azino-di-[3-ethyl-
benzthiasoline sulphonate] (ABTS) to ABTSþ by metmyo-
globin. Inhibition of absorption at 750 nm is measured and
compared to that of the water soluble tocopherol analog,
Trolox. The data therefore reflect the net antioxidant
capacity of proteins (e.g., albumin) and small molecules
(e.g., GSH, vitamin E, and vitamin C) normally present in
plasma.24
H2O2 assays
We assayed urine H2O2 using the xylenol orange detection
method for quantifying oxidation of ferrous to ferric ions by
H2O2 (Urinary Hydrogen Peroxide Assay, Catalog No.
706011, Cayman Chemical Company, Ann Arbor, MI).25
Catalase was added to duplicate assay wells to confirm
the specificity for H2O2. Ferric ion binds to the dye xylenol
orange to form a stable colored complex. Urine samples
with or without catalase were mixed with reagent and
rocked at room temperature for 60 min. Absorbance was
recorded at 595 nm.
Statistical analyses
Data were expressed as arithmetic means  SD or medians
with [25e75th] percentiles indicated, if the distribution of
values were non Gaussian. Pre- and post-exercise BNP and
markers of oxidant stress were compared using the signed
rank test (i.e., pre- and post-exercise data were paired).
Comparisons of IPF pre-exercise values to normal controls
were not tested statistically, because the groups were not
studied contemporaneously. Data from the control groups
are included in the figures to illustrate the distribution
of the data. In post hoc exploratory analyses, Pearson
product moment correlations were calculated to find
whether any of the plasma or urine markers of oxidant
stress correlated with the post-exercise (nadir) SaO2
or the decrease in SaO2 during exercise. Statistical calcu-
lations were done using SigmaStat (Systat Software,
San Jose, CA).
Table 1 Baseline characteristics of the subjects.
Variable Overall mean at
baseline (n Z 29)
Male gender 23
Age (years) 709a
Months after diagnosis 24  12
Previous smokers 25 (86%)b
Oxygen use 15 (52%)
6-MWD (meters) 347  71
Bicycle exercise time (seconds) 220  170
Borg dyspnea index before exercise 1.0  1.4
Borg dyspnea index after exercise 3.9  1.9
FVC (% predicted) 62  12
FEV1/FVC (ratio) 0.87  0.14
DLCO (% predicted) 42  9
TLC (% predicted) 61  10
PaO2 (mm Hg) 81  10
SaO2 (mm Hg) before exercise 97  2
SaO2 (mm Hg) after exercise 92  5
a Data are means  SD.
b Data are numbers of individuals (percent of total).
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Figure 1 Plasma BNP concentrations before and after exer-
cise. Plasma NT-proBNP values are shown as the concentrations
in pg/mL. The median, 25e75th percentiles (box) and 5e95th
percentiles (whiskers) for 29 IPF subjects are shown. The cor-
responding values in plasma established from 6 normal controls
averaging 50 years of age are shown by the box-whisker plot on
the right. Pre-0, before exercise; post-0, after exercise.
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Characteristics of the subjects and controls
Demographic and physiological characteristics of the 29 IPF
subjects are given in Table 1. Normal controls recruited
from our laboratory staff were in apparently good health.
We used plasma and urine from these individuals to vali-
date the assay protocols in our laboratory. By design,
normal controls did not complete the exercise protocol.
Only data from volunteers who were over 40 years of age
(an entry criterion for the study) are shown here. Those
individuals (n Z 6; 2 were female) averaged 50  6 (SD)
years of age.
Standardized exercise tests
Twenty-nine IPF subjects exercised in the sitting position
for 222  170 (SD) seconds on the recumbent bicycle at
a constant workload of 50 W. Exercise was limited by
dyspnea or fatigue, i.e., the subjects chose when to stop.
No adverse events occurred during exercise. Blood and
urine samples were obtained immediately before and after
exercise as described above.
Plasma lactate assays and oxygen saturation data
The 29 subjects’ median [25e75th percentiles] plasma
lactate concentration before exercise was 1.4 [1.1e2.0],
and it increased significantly after exercise to 2.3 [2.0e2.9]
mM (P < 0.001 by signed rank test). The median SaO2
before exercise was 97 [96e98] %, and after exercise it
decreased significantly to 91 [88e95] % (P < 0.001 by signed
rank test).
NT-proBNP assays
The pre-exercise median NT-proBNP [25e75th percentiles]
was 108 [48e329] ng/mL, and the post-exercise median was
112 [51e314]. Some subjects’ NT-proBNP levels increased
substantially after exercise. Normals’ (n Z 6) NT-proBNP
levels were 36 [23e53] pg/mL. These data are shown in
Fig. 1. A number of individuals in this study had NT-proBNP
levels (after conversion to the equivalent BNP concentra-
tion) in the range that Leucthe et al. report for IPF patients
with pulmonary hypertension.18
Urine creatinine assays
The subjects’ median urine creatinine concentration
[25e75th percentiles] was 114 [60e179] mg/dL and
the normals’ urine creatinine concentration was 85
[53e179] mg/dL.
Plasma isoprostane assays
Isoprostanes are produced in vivo by free radical catalyzed
oxidation of membrane bound polyunsaturated fatty
acids.26 IPF plasma isoprostane values did not change
significantly after exercise, but they clearly exceeded thenormal control range for the assay. These data are shown in
Fig. 2.
Urine isoprostane assays
IPF urine isoprostane concentrations increased significantly
after exercise (P Z 0.047 compared to pre-exercise by
signed ranks test). These data are shown in Fig. 3.
Increased post-exercise urine isoprostanes correlated
significantly with decreased SaO2 after exercise
(r Z 0.434; P Z 0.0438).
Plasma total antioxidant capacity assay
After standardized bicycle exercise, the IPF plasma TAC
decreased significantly, demonstrating increased systemic
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Figure 2 Plasma isoprostane concentrations before and after
exercise. Data shown are plasma isoprostane concentrations in
pg/mL. The median, 25e75th percentile (box) and 5e95th
percentiles (whiskers) for 29 IPF subjects are shown. The cor-
responding values in plasma established from 16 normal
controls described previously (see reference 20) are shown by
the box-whisker plot on the right. The plasma isoprostane
values did not change significantly after exercise, but they
apparently exceeded the normal control range for the assay.
Pre-0, before exercise; post-0, after exercise.
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Figure 4 Plasma total antioxidant capacity before and after
exercise. Data shown are plasma total antioxidant capacity in
Trolox equivalents [mM]. The median, 25e75th percentile
(box) and 5e95th percentiles (whiskers) for 29 IPF subjects are
shown. The corresponding values in plasma established from 6
normal controls averaging 50 years of age are shown by the
box-whisker plot on the right. The plasma TAC decreased
significantly after exercise (*, P < 0.001 post-exercise
compared to pre-exercise by signed rank test). Pre-0, before
exercise; post-0, after exercise.
Exercise and oxidant stress in IPF 1923oxidant stress (P < 0.001 compared to pre-exercise by
signed ranks test). As shown above, the decrease in TAC
was accompanied by corresponding increases in lactate and
hypoxemia after exercise. These data are shown in Fig. 4.
Nitrate/nitrite assays
IPF patients have a range of total nitrite concentrations in
the urine and blood that is easily measurable using the
Griess reaction. The values are quite comparable to normal
human data in the literature.27 These data are shown in
Table 2.pre-0 post-0 Normals
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Figure 3 Urine isoprostane concentrations before and after
exercise. Data shown are urine isoprostane concentrations in
ng/g creatinine. The median, 25e75th percentile (box) and
5e95th percentiles (whiskers) for 29 IPF subjects are shown.
The corresponding urine values established from 16 normal
controls reported previously (see reference 20) is shown by the
box-whisker plot on the right. IPF urine isoprostane concen-
tration increased significantly after exercise. Pre-0, before
exercise; post-0, after exercise. (*, P Z 0.047 post-exercise
compared to pre-exercise by signed rank test).Urine H2O2 assay
A wide range of H2O2 values was found; some IPF patients
have post-exercise urine H2O2 concentrations several fold
above the pre-exercise and normal values. However,
because of the high variability, no significant differences
were found. These data are shown in Fig. 5.
Discussion
Summary
An underlying rationale for the present study was the
previously reported oxidative and nitrosative stress in both
epithelial lining fluid and circulation of IPF patients.4,28,29
We reasoned that exercise would exacerbate systemic
oxidant stress in IPF patients, perhaps related to impaired
oxygenation and resulting cellular hypoxia as in COPD.30,31
We studied patients selected for enrollment in
a randomized clinical trial of sildenafil, a pulmonary vaso-
dilator, for IPF.17 Enrolled patients were quite typical of IPF
patients followed in the outpatient clinic, and their diag-
noses were based on the presently accepted ATS-ERS case
definition.1,2
Plasma NT-proBNP is elevated in IPF patients
Despite the modest increase in pulmonary artery systolic
pressure (estimated echocardiographically in the mid
thirties) required for entry into the trial, we found that IPF
patients had plasma NT-proBNP levels clearly above the six
normals, as shown in Fig. 1. Elevated brain natriuretic
peptide (BNP) levels correlate well with significant pulmo-
nary hypertension in patients with chronic lung diseases,
including idiopathic pulmonary fibrosis.18 None of our
subjects had clinically or echocardiographically evident left
Table 2 Plasma and urine nitrite concentrations.a
Pre-exercise Post-exercise Controls Pb
Plasma total nitrite [mM] 12 [8e15] 10 [7e14] 7 [4e11] 0.314
Urine total nitrite [mmol/g creatinine] 216 [156e341] 218 [133e353] 293 [190e542] 0.509
a Data from 29 subjects and 6 controls are medians with the [25e75th] percentiles shown. Total nitrite represents the sum of nitrite
and nitrate after reduction in vitro with nitrate reductase.
b Pre-exercise compared to post-exercise value by signed rank test.
1924 R. Jackson et al.ventricular failure, confirming that high NT-proBNP levels
were likely related to the increase in pulmonary artery
pressure that typifies IPF. The range and median of post-
exercise NT-proBNP values appeared similar to the pre-
exercise values as shown in Fig. 1. Nineteen of 29 individual
subjects had detectable increases in their NT-proBNP
values after exercise. While some individual patients had
both high post-exercise NT-proBNP and elevated systolic
pulmonary artery pressure (RVSP) by echocardiography, no
significant statistical correlation could be found by regres-
sion analysis. The lack of correlation was due to individual
variability and the small number of subjects in the trial.
Increased pulmonary vascular resistance and impaired right
ventricular pressure appear to be key factors in exercise
limitation of IPF patients.
Oxidant stress is an important mechanism in IPF
Oxidative stress in IPF is detectable using various biomarkers
(e.g., protein carbonyls, antioxidant capacity, thio-
barbituric reactive substances) in bronchoalveolar lavage
fluid (BALF) and plasma.4,28 For example, 8-isoprostanes
(i.e., F2-isoprostanes), a product of non enzymatic, radical
catalyzed lipid peroxidation are found in BALF of patients007
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Figure 5 Urine hydrogen peroxide concentration. Data
shown are urine H2O2 concentrations in nmol/mg creatinine.
The median, 25e75th percentile (box) and 5e95th percentiles
(whiskers) for 29 IPF subjects are shown. The corresponding
values in urine established from 6 normal controls averaging 50
years of age is shown by the box-whisker plot on the right. A
range of values was found; some IPF patients have post-exer-
cise urine H2O2 concentrations several fold above the pre-0 and
normal values. However, because of the variability, no signifi-
cant differences were found. Pre-0, before exercise; post-0,
after exercise.with interstitial and other chronic lung diseases.26 Depletion
of lung GSH is relevant to the pathogenesis of IPF,32,33 as is
implied by a recent clinical trial. Deterioration of vital
capacity (VC) and diffusing capacity (DLCO) were delayed
significantly in the N-acetylcysteine group.10
Plasma and urine isoprostanes indicate systemic
oxidant stress in IPF
F2-isoprostanes are prostaglandin-like compounds, derived
from esterified arachidonic acid by non enzymatic, free
radical catalyzed reactions. They have provided evidence of
oxidative stress in a number of disease states including
atherosclerosis, chronic obstructive pulmonary disease and
neurodegenerative conditions (for review, see reference 26).
We detected significantly increased urine isoprostanes
after low level exercise. Elevated urine isoprostanes reflect
rapid renal clearance of lipid peroxidation products from
the circulation. While we cannot eliminate renal produc-
tion of isoprostanes as the source, the kidney presumably
remains well perfused during exercise and well oxygenated
compared to skeletal muscle.
Plasma isoprostane levels in IPF patients are several fold
higher than those in controls’ plasma, as shown in Fig. 2.
We did not detect an increase after exercise, perhaps
because of the already high levels. While we and others
21,26 take this to represent convincing evidence of oxidant
stress, the potent vasoconstrictor activities F2-isoprostanes
are also plausibly related to the increase in pulmonary
artery pressure found on echocardiography. Isoprostanes
are potent vasoactive thromboxane receptor agonists,
demonstrating also a potential pathophysiological role as
mediators of pulmonary hypertension.26 Thus, finding
increased isoprostanes is mechanistically relevant to exer-
cise induced increase in pulmonary vascular resistance and
associated right ventricular dysfunction.
Plasma antioxidant capacity decreases after
exercise
IPF patients at rest had plasma antioxidant capacity (TAC)
comparable to or higher than normal controls. This result
obviously differs from the findings of Rahman et al., who
reported that IPF patients had diminished TAC at rest.4 Over
one-half of the subjects in their study were current cigarette
smokers (while none of our subjects were active smokers),
and this may represent the greatest difference between our
study populations. Our patients were strictly classified using
contemporary criteria 1,2 and none were treated with
corticosteroids or experimental therapy at the time of these
Exercise and oxidant stress in IPF 1925measurements, so the patient population we studied
differed significantly from that described by Rahman et al.4
IPF patients developed a large and significant decrease
in plasma TAC after exercise as shown in Fig. 4, reminiscent
of exercise induced oxidant stress described in chronic
obstructive pulmonary disease (COPD) patients.29 This
oxidant stress is accompanied by hypoxemia and lactate
production, indicating that low level exercise has signifi-
cant metabolic effects in IPF subjects. TAC represents the
capacity of plasma to inhibit an in vitro oxidation reaction.
It is a nonspecific functional assay and likely reflects the
availability of reduced sulfhydryl groups on albumin in
addition to low molecular weight antioxidants such as
nonprotein sulfhydryls, ascorbic acid, tocopherol and
membrane lipids that compete as targets of oxidation.24
Changes in TAC after exercise are not specific for IPF but
rather represent a general indication of oxidant stress that
may occur in various disease states. For example, asthma
patients are found to have significantly decreased total
antioxidant status during acute exacerbations.34 Similarly,
TAC is lower than normal in COPD patients’ plasma, and it
correlates with the severity of airway obstruction.35 TAC is
decreased in a number of other pathologies, including
severe sepsis.36
Urinary hydrogen peroxide as a marker of oxidant
stress
While we found no significant increase in urinary H2O2 after
exercise, some individual post-exercise values were high
compared to those at rest and to the normal controls as
shown in Fig. 5. Because not all urine samples contained
measurable H2O2, exploratory analysis was limited to those
samples in which we could measure H2O2. The urinary
concentration of hydrogen peroxide is increased in patients
with malignancies, where it correlates with increased
plasma hydrogen peroxide and erythrocyte malondialde-
hyde.37 Although auto oxidation reactions in urine could
generate H2O2,
25 elevated urinary H2O2 is regarded as
a marker of systemic oxidant stress in malignancies.37
Nitrosative stress in IPF
Reactive nitrogen species (RNS), which interact with ROS,
also contribute importantly to epithelial injury in IPF.
Myeloperoxidase (MPO) and nitrotyrosine (NT) co-localize in
a number of inflammatory lesions.38 Finding MPO and NT
together suggests that NO2
 (the major end product of NO
metabolism) and HOCl react to produce NO2, which
accounts for tyrosine nitration. Lung sections from IPF
patients stain strongly positive for nitrotyrosine (NT) and
inducible nitric oxide synthase (iNOS) in alveolar macro-
phages, neutrophils and alveolar epithelium.29
Although nitrosative stress is evident in IPF lung
sections,29 we found no increase in IPF plasma total nitrite
concentration compared to controls as shown in Table 2.
We likewise found no differences in urine nitrite concen-
tration after exercise. This observation reflects restriction
of the well described nitrosative stress found in IPF patients
to alveolar compartment.Systemic oxidant stress and exercise in IPF and
other chronic lung disease
We found a significant increase in urine isoprostane
concentration after low level exercise as shown in Fig. 3,
confirming our hypothesis that low level exercise would
exacerbate oxidant stress in IPF patients. Since urine iso-
prostanes were negatively correlated with post-exercise
SaO2, the observed increase in isoprostanes is associated
with evidence for hypoxemia.
We found a significant decrease in hemoglobin oxygen
saturation and a small but significant increase in lactate
after low level exercise, suggesting that some subjects
exercised at near maximal capacity. Lactate production
reflects the integration of ATP production and its cellular
utilization, so that efficient lactate uptake may result in
relatively low circulating concentrations that reflect
adaptation to hypoxia. Plasma lactate may not reflect
anaerobic glycolysis in muscles, as aerobic overproduction
of pyruvate may occur early during maximal exercise.39
IPF patients we studied developed hypoxemia as shown
by decreased SaO2 and increased lactate concentrations,
along with increases in oxidant stress after exercise. While
an increase in lactic acid production is typical of severe
exercise, it occurred here at a rather low level of exertion
(50 W). The increase in lactate may have been blunted
because of the subjects’ exercise limitation due to increased
pulmonary vascular resistance and right ventricular
dysfunction.
Exercise as well as hypoxia per se imposes oxidative
stress on skeletal muscle.40,41 Increases in myocardial and
skeletal muscle free radical concentration confirm that
excess ROS produced during exercise precede fatigue.41
While the source of ROS produced by muscle cells is not
entirely clear, it is likely that mitochondria, enzymes and
activated phagocytes all contribute.42 Significant muscle
cell hypoxia may occur during exercise in patients with
impaired gas exchange and systemic hypoxemia.30 Hypoxia
increases production of ROS by mitochondria, yet indirect
evidence from manganese-containing superoxide dismutase
heterozygous knockout mice indicates that mitochondria
may not be the only source of O2
.42
Glutathione metabolism is also clearly affected by
exercise. Prolonged submaximal exercise by humans causes
a decrease in reduced glutathione and a concomitant
increase in GSSG.43 Allopurinol inhibited the increase in
GSSG/GSH and lipid peroxidation, otherwise observed in
exercising COPD patients.44 Changes in exercise capacity
were not measured, although inhibition of ROS production,
e.g., with allopurinol, would conceivably prevent skeletal
muscle dysfunction and increase exercise capacity.
Redox signaling may also be required for adaptation to
exercise. Endurance exercise training can reduce oxidative
stress after exhaustive exercise and may permit increased
functional capacity.45,46 Exercise training increases CuZn-
containing superoxide dismutase and decreases p67phox,
ERK phosphorylation and malondialdehyde production.40
Although we obtained novel and valuable data from this
study, we recognize several intrinsic limitations in its design
and execution. The study population was small, as would be
expected in a single center trial. By design, each subject
NO nitric oxide radical
NT nitrotyrosine
NT-proBNP amino terminal pro brain natriuretic
peptide
PAPsys systolic pulmonary arterial pressure
PDE5 phosphodiesterase five
PAH pulmonary arterial hypertension
O2
- superoxide anion
RCT randomized controlled trial
RVESP right ventricular end systolic pressure
SaO2 arterial oxygen saturation
SD standard deviation
SOD superoxide dismutase
TAC total antioxidant capacity (of plasma)
TGF-b transforming growth factor-beta
1926 R. Jackson et al.served as his or her own control, so we did not compare
responses of IPF patients to those of disease controls (e.g.,
COPD or sarcoid) or to normals. We chose rather to assess
endurance at a low, constant workload as the stimulus to
oxidant stress. Maximum oxygen consumption was not
measured, although it is likely that protocol would have
provoked a greater degree of oxidative stress. The controls
did not participate in the exercise protocol because of the
planned, paired nature of the design. The controls tended
to be younger and healthier than the IPF patients we
studied in the exercise protocol. Despite these limitations,
which themselves raise testable hypotheses, the paired
design effectively allowed us to detect significant intra-
group differences after exercise.
Conclusions
A number of important new observations came from this
trial. Finding that NT-proBNP is elevated in typical IPF
patients and that two markers of oxidant stress, decreased
plasma TAC and increased urine isoprostanes occur after
low level exercise and are associated with hypoxemia, is
important. Such observations could lead to testing the
hypotheses that systemic oxidant stress may be due to
cellular hypoxia and that oxidant stress during exercise may
be a factor that limits endurance of IPF patients. Taken
together, these results show that IPF patients develop
hypoxemia and oxidant stress at low levels of exercise and
suggest that isoprostanes could therein contribute to
increased pulmonary vascular resistance.Acknowledgments
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